View Older Stories View More Recent Stories

Mar 22, 2022 11:27AM Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
Mar 7, 2022 11:56AM Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
Feb 25, 2022 09:01AM Myovant Sciences (MYOV) Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
Feb 25, 2022 09:00AM Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
Feb 25, 2022 09:00AM Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
Feb 7, 2022 08:30AM Myovant Sciences to Present at Upcoming Investor Conferences
Feb 7, 2022 08:30AM Myovant Sciences to Present at Upcoming Investor Conferences
Jan 26, 2022 06:55AM Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
Jan 26, 2022 06:55AM Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
Jan 12, 2022 08:30AM Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022
Jan 12, 2022 08:30AM Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022
Jan 10, 2022 06:56AM Myovant Sciences (MYOV) Reports Prelim Q3 Results
Jan 10, 2022 06:55AM Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
Jan 3, 2022 08:30AM Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
Jan 3, 2022 08:30AM Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 20, 2021 12:11PM Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA®
Dec 10, 2021 10:26AM Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
Nov 23, 2021 08:30AM Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
Nov 23, 2021 08:30AM Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
Nov 8, 2021 08:00AM Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
Nov 8, 2021 06:06AM Myovant Sciences (MYOV) Appoints Nancy Valente to its Board
Nov 8, 2021 06:00AM Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
Nov 8, 2021 06:00AM Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
Nov 4, 2021 02:05PM Spirovant Presents Preclinical Data Showing SP-101 Restores CF Transmembrane Conductance Regulator Function at the 2021 North American Cystic Fibrosis Conference
Oct 26, 2021 06:55AM Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
Oct 19, 2021 06:58AM Myovant Sciences (MYOV) and Pfizer (PFE) Report Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis
Oct 19, 2021 06:58AM Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Oct 19, 2021 06:58AM Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Oct 12, 2021 08:30AM Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
Oct 12, 2021 08:30AM Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
Oct 8, 2021 08:09PM Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Oct 8, 2021 08:09PM Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Sep 9, 2021 06:59AM Myovant Sciences (MYOV), Pfizer (PFE) Announce FDA Acceptance of sNDA for MYFEMBREE for Management of Moderate to Severe Pain Associated With Endometriosis
Sep 9, 2021 06:58AM Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Sep 9, 2021 06:58AM Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Sep 1, 2021 08:30AM Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
Sep 1, 2021 08:30AM Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
Aug 26, 2021 09:00AM Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
Aug 26, 2021 09:00AM Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
Aug 12, 2021 04:46PM Myovant Sciences (MYOV) Appoints Uneek Mehra as Chief Financial and Business Officer
Aug 12, 2021 04:01PM Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
Aug 12, 2021 04:01PM Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
Aug 4, 2021 09:49AM Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
Aug 4, 2021 09:49AM Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
Jul 28, 2021 06:55AM Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
Jul 20, 2021 02:00AM Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
Jul 20, 2021 02:00AM Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
Jul 14, 2021 08:30AM Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
Jul 14, 2021 08:30AM Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
Jun 1, 2021 08:30AM Myovant Sciences to Present at Upcoming Investor Conferences
View More Recent Stories View Older Stories